Rounding the Far Post - Hold and Buy OncolyticsToday’s AGM will be different than prior ones. This morning’s timed announcement of the supply agreement is another indication that the commercialization of Reolysin is rounding the corner to the home stretch. AMGN paid $1 billion for Biovex. The market cap of ONC is under $390 million. The days of the buy side manipulation are coming to an end and the shorts have limited time to cover their bets. Hold and buy Oncolytics. How many trading days until the World Lung Cancer Conference?